Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update

Catherine S. Diefenbach, Brad S. Kahl, Lalita Banerjee, Andrew K. McMillan, Fiona Miall, Javier Briones, Raul Cordoba, John M. Burke, Jamie Hirata, Sunil Sharma, Lisa Musick, Pau Abrisqueta Costa

Blood (2022) 140 (Supplement 1): 2286–2288.

https://doi.org/10.1182/blood-2022-157720

Published: 2022

Journal Articles

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

Blood (2020) 135 (15): 1255–1269.

https://doi.org/10.1182/blood.2019002922

Published: 2020

Includes: Supplemental data

Journal Articles

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Vrajesh Karkhanis, PhD, Bernardo H Lara, Prithviraj Bose, MD, Lucia Masarova, Tapan M. Kadia, MD, Nancy Shao, Isean Bhalla, James V Maher, Joseph D. Khoury, MD, Sunil Sharma, MD, Taghi Manshouri, PhD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 1274.

https://doi.org/10.1182/blood-2019-130783

Published: 2019

Journal Articles

Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells

Warren Fiskus, BSc, PhD, Christopher Peter Mill, PhD BA, Raffaella Soldi, Roulan Han, Dyana T. Saenz, PhD, Agnieszka J Nowak, Baohua Sun, MD PhD, David N Saenz, Courtney D. DiNardo, MD MSc, Gautam Borthakur, MD, Tapan M. Kadia, MD, Wendy Jin, Thurika Ganesh, Vaishnavi Rao, Joseph David Khoury, MD, Sunil Sharma, MD, Kapil N. Bhalla, MD

Blood (2018) 132 (Supplement 1): 3930.

https://doi.org/10.1182/blood-2018-99-114198

Published: 2018

Journal Articles

Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis

Dyana T. Saenz, PhD, Warren Fiskus, BSc,PhD, Taghi Manshouri, PhD, David N Saenz, Raffaella Soldi, Baohua Sun, MD PhD, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, Steven M. Kornblau, MD, Prithviraj Bose, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Lucia Masarova, MD, Steve Horrigan, Joseph David Khoury, MD, Sunil Sharma, MD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2018) 132 (Supplement 1): 177.

https://doi.org/10.1182/blood-2018-177

Published: 2018

Journal Articles

GFI1B Splice Variants Differentially Regulate Transcription and Megakaryocyte/Erythrocyte Fate in Hematopoiesis

David McClellan, BS, Jason Singer, PhD, Matthew Velinder, PhD, Diana Bareyan, MS, Mattie Casey, BA, Helena Lucente, BS, Alexis Weston, BS, Sunil Sharma, MD, Michael Engel, MD PhD

Blood (2017) 130 (Supplement 1): 2430.

https://doi.org/10.1182/blood.V130.Suppl_1.2430.2430

Published: 2017

Journal Articles

GFI1 Snag Domain Methylation Directs LSD1 Recruitment to Control Transcription and Cell Fate Determination in Hematopoiesis

Matthew E Velinder, BS, Jason Singer, PhD, Jessica Meznarich, MD, Emily R Theisen, PhD, James Fulcher, BS, Christopher Tracy, PhD, Sarah Franklin, PhD, Sunil Sharma, MD, Michael E Engel, MD PhD

Blood (2015) 126 (23): 46.

https://doi.org/10.1182/blood.V126.23.46.46

Published: 2015

Journal Articles

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib

Baohua Sun, Bhavin Shah, Warren Fiskus, Jun Qi, Kimal Rajapakshe, Cristian Coarfa, Li Li, Santhana G. T. Devaraj, Sunil Sharma, Liang Zhang, Michael L. Wang, Dyana T. Saenz, Stephanie Krieger, James E. Bradner, Kapil N. Bhalla

Blood (2015) 126 (13): 1565–1574.

https://doi.org/10.1182/blood-2015-04-639542

Published: 2015

Includes: Supplemental data

Journal Articles

Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells

Santhana G. T. Devaraj, PhD, Warren Fiskus, PhD, Bhavin Shah, Sunil Sharma, Jun Qi, PhD, Baohua Sun, MD PhD, Saikat Saha, PhD, Swaminathan Padmanabhan Iyer, MD, Youli Zu, MD PhD, James Bradner, MD, Kapil N. Bhalla, MD

Blood (2014) 124 (21): 3534.

https://doi.org/10.1182/blood.V124.21.3534.3534

Published: 2014

Journal Articles

Combined Targeting of β-Catenin and FLT-3 Is Synergistically Lethal Against Cultured and Primary AML Blast Progenitor Cells Expressing FLT3 Internal Tandem Duplication (ITD)

Saikat Saha, PhD, Warren Fiskus, PhD, Sunil Sharma, Bhavin Shah, Anna T Rogojina, Santhana G. T. Devaraj, PhD, Baohua Sun, MD PhD, Christopher Leveque, MD, Youli Zu, MD PhD, Swaminathan Padmanabhan Iyer, MD, Kapil N. Bhalla, MD

Blood (2014) 124 (21): 618.

https://doi.org/10.1182/blood.V124.21.618.618

Published: 2014

Journal Articles

Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells

Baohua Sun, MD PhD, Warren Fiskus, PhD, Bhavin Shah, Jun Qi, PhD, Santhana G. T. Devaraj, PhD, Swaminathan Padmanabhan Iyer, MD, Sunil Sharma, James Bradner, MD, Youli Zu, MD PhD, Kapil N. Bhalla, MD

Blood (2014) 124 (21): 918.

https://doi.org/10.1182/blood.V124.21.918.918

Published: 2014

Journal Articles

Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD

Melissa Rodriguez, M.D., Ph.D, Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S., Bhavin Shah, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 3821.

https://doi.org/10.1182/blood.V122.21.3821.3821

Published: 2013

Journal Articles

Notch Alters Sumoylation To Govern GFI1 Protein Stability and Support Its Transcriptional Repression Function

Jason Singer, PhD, Daniel Andrade, PhD, Diana Bareyan, MS, David McClellan, BS, Helena Lucente, BS, Matthew Velinder, BS, Mahesh Chandrasekharan, PhD, Emily Theisen, BS, Fang Liu, PhD, Sunil Sharma, MD, Luke Maese, DO, Michael E Engel, MD, PhD

Blood (2013) 122 (21): 3793.

https://doi.org/10.1182/blood.V122.21.3793.3793

Published: 2013

Journal Articles

Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells

John A Valenta, M.S., Warren Fiskus, Ph.D, Taghi Manshouri, Ph.D., Sunil Sharma, MD, Jun Qi, PhD, Leasha J Schaub, M.S., Bhavin Shah, Melissa Rodriguez, M.D., Ph.D, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, Srdan Verstovsek, MD, PhD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 2842.

https://doi.org/10.1182/blood.V122.21.2842.2842

Published: 2013

Journal Articles

BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells

Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S., Bhavin Shah, Karissa Peth, Laxmi U.M.R. Jakkula, PhD, Melissa Rodriguez, M.D., Ph.D, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 485.

https://doi.org/10.1182/blood.V122.21.485.485

Published: 2013

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

Kapil Bhalla, MD, Warren Fiskus, Ph.D., Stephen K. Horrigan, PhD, Sunil Abhyankar, MD, Joseph McGuirk, DO, Sunil Sharma, MD

Blood (2012) 120 (21): 287.

https://doi.org/10.1182/blood.V120.21.287.287

Published: 2012

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

Warren Fiskus, Ph.D., Sunil Sharma, M.D., Sunil Abhyankar, MD, Joseph McGuirk, DO, David J. Bearss, PhD, Kapil Bhalla, MD

Blood (2012) 120 (21): 868.

https://doi.org/10.1182/blood.V120.21.868.868

Published: 2012

Journal Articles

A Novel Dual AXL/Mertk and Aurora Kinase Inhibitor Active Against T Cell Acute Lymphoblastic Leukemia

Anupam Verma, MD, J. Kimble Frazer, MD, PhD, Alesia Trakhimets, William Heaton, Jared Bearrs, Steven Warner, PhD, David Bearrs, PhD, Sunil Sharma, MD

Blood (2011) 118 (21): 1519.

https://doi.org/10.1182/blood.V118.21.1519.1519

Published: 2011

Journal Articles

Treatment with β-Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells

Warren Fiskus, PhD, Jacqueline Smith, MS, Uma Mudunuru, MS, Stacey Hembruff, MS, Ruben Reyes, MD, Sunil Abhyankar, MD, Joseph McGuirk, DO, Omar S. Aljitawi, MD, Siddhartha Ganguly, MD, Stephen K. Horrigan, PhD, Sunil Sharma, MD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 65.

https://doi.org/10.1182/blood.V118.21.65.65

Published: 2011

Journal Articles

Effects of Renal Function on the Pharmacokinetics of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Sunil Sharma, MD, Emile Voest, MD, PhD, Nicole Hagner, MD, P.O. Witteveen, MD, PhD, Martijn Lolkema, MD, PhD, Neeraj Agarwal, MD, Sue-zette Valera, Jason Li, PhD, Derek Mires, Maria Grazia Porro, PhD, Margaret M. Woo, PharmD, Dagmar Hess, MD

Blood (2011) 118 (21): 5001.

https://doi.org/10.1182/blood.V118.21.5001.5001

Published: 2011

NARROW

A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells

Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis

GFI1B Splice Variants Differentially Regulate Transcription and Megakaryocyte/Erythrocyte Fate in Hematopoiesis

GFI1 Snag Domain Methylation Directs LSD1 Recruitment to Control Transcription and Cell Fate Determination in Hematopoiesis

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib

Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells

Combined Targeting of β-Catenin and FLT-3 Is Synergistically Lethal Against Cultured and Primary AML Blast Progenitor Cells Expressing FLT3 Internal Tandem Duplication (ITD)

Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells

Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD

Notch Alters Sumoylation To Govern GFI1 Protein Stability and Support Its Transcriptional Repression Function

Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells

BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

A Novel Dual AXL/Mertk and Aurora Kinase Inhibitor Active Against T Cell Acute Lymphoblastic Leukemia

Treatment with β-Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells

Effects of Renal Function on the Pharmacokinetics of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only